Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cipla-NiPPharma In Respiratory Device Deal?

Executive Summary

Cipla Ltd. is speculated to have struck a deal with Japan's NiPPharma Co., Ltd for a device apparently meant for the Indian firm's generic Advair dry powder inhaler (DPI) but some analysts suggest that limited visibility around the trials of the firm's salmeterol + fluticasone combination in the US stay a concern for now.

You may also be interested in...



What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK

The company showed signs of stabilization in the first quarter, as Witty insisted his diversified strategy is beginning to pay off. But a new CEO will have to contend with the potential entry of Advair generics.

Mylan's Generic Advair FDA Filing Puts Added Squeeze On GSK

The increasing urgency for GlaxoSmithKline PLC to build up its overall respiratory portfolio was underscored when Mylan NV confirmed it has submitted an abbreviated new drug application (ANDA) to the FDA for launch of the first generic alternative to GSK's top-selling Seretide Evohaler (salmeterol xinafoate + fluticasone propionate), known in the US as Advair Diskus.

Syngene COO On Delivering Cost Gains For mRNA Products

Syngene’s COO, Mahesh Bhalgat, said the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company's capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC065371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel